Breaking News, Trials & Filings

Ferring’s First-in-Class Microbiota-Based Live Biotherapeutic Approved

REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI).

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ferring Pharmaceuticals received approval from the U.S. FDA for REBYOTA (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.   The approval is based on results from the clinical program including the Phase 3 PUNCH CD3 trial in which a single dose of REBYOTA demonstrated superiorit...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters